Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback